EGE.V. Gushanskaya

E.V. Gushanskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E.V. Gushanskaya has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dysmorphia with gender identity disorder

    by V.E. Medvedev, Yu.P. Sivolap, V.I. Frolova, E.V. Gushanskaya, S.I. Gushanskiy, N.L. Zuikova, I.V. Salyntsev

    The frequency of comorbidity of body dysmorphic disorder (DD) and gender identification disorder (FIR) is 26.9% -100%. At the same time, the nature of the clinico-dynamic interrelations between dysmorphia and FIR has not been sufficiently studied. Goal: To study the nature of the clinical and dynamic interrelationships of EPI in patients with schizophrenic spectrum disorders. Materials and methods: The study included patients of both sexes aged 18 to 65 years who reported dissatisfaction with their biological sex.Clinical-psychopathological, clinical-catamnestic and statistical research methods were used. Results. In the course of the study, a typological differentiation of TDR with FIR was carried out, which was determined by the structure and dynamics of mental disorders. In all patients, DTP preceded the formation of EPI. In addition to DTP, patients within the framework had depersonalization (68.6%) and autodestructive tendencies (48.6%). In all observations, FIR developed according to the mechanism of a sudden “informational epiphany”, with a reassessment of past events, pseudo-reminiscences and the development of overwhelming ideas of sexual metamorphosis. EPI in patients with schizophrenia is formed within the framework of simple monothematic gender dysmorphia (22.9%) or against the background of complex polythematic dysmorphia with non-feminine emotional-volitional disorders (77.9%) of DD. The further dynamics of the EPI is determined by the course of the schizophrenic process (low-progressive, paroxysmal). Treatment of DTP with FIR is a complex task and is carried out using antidepressants and modern antipsychotics, as well as psychotherapy. Conclusion: The possible influence of mental illness on the clinical and dynamic characteristics of patients necessitates the further study of TDR in outpatient patients with isolated EPI, as well as EPI in other comorbid mental pathologies such as personality disorders, affective disorders, and other disorders.

  • Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia

    by S.I. Gavrilova, I.V. Kolykhalov, N.M. Mikhaylova, E.V. Ponomareva, Ya.B. Fedorova, V.E. Medvedev, V.I. Frolova, E.V. Gushanskaya, I.V. Litvinenko, A.YU. Emelin, et al.

    OBJECTIVE Evaluation of the efficacy and safety of the drug Acatinol Memantine, 20 mg (once daily) in comparison with the drug Acatinol Memantine, 10 mg (twice daily) in patients with moderate to moderate severe vascular dementia. MATERIAL AND METHODS The study included 130 patients aged 50—85 years of both sexes with instrumentally and clinically confirmed vascular dementia. The patients were randomized into 2 groups. Group I consisted of 65 patients receiving Akatinol Memantine, 20 mg once daily, group II — 65 patients receiving Akatinol Memantine, 10 mg twice daily for 24 weeks. Clinical, parametric and statistical research methods were used. The Alzheimer’s disease assessment scale, the cognitive subscale (ADAS-cog), the short mental Status Assessment Scale (MMSE) and the general clinical impression scale for patients condition and illness severity (CGI-C and CGI-S) and the Hamilton Depression Rating scale (HAM-D) were used. Adverse events were collected and analyzed. RESULTS At week 24, both groups showed statistically significant positive change in ADAS-cog total score: in group I the total score was 27.2±8.76 points (absolute difference from baseline 3.5 points; pp<0.01) with no statistically significant differences between groups. Evaluation of secondary efficacy criteria (change in ADAS-cog total score at week 12 and MMSE at weeks 4, 12, and 24) also revealed statistically significant benefit in both groups compared to baseline with no significant differences between groups. Statistically significant improvement was noticed on CGI-S and CGI-C scales in both groups. Akatinol Memantine was safe and well tolerated in both groups. CONCLUSION The study showed no lesser efficacy and safety of Akatinol Memantine, 20 mg (once daily) compared to Akatinol Memantine, 10 mg (twice daily) in patients with moderate and moderately severe vascular dementia.


  • Clinical aspects of the use of imidazopyridine derivatives in the treatment of sleep disorders associated with post-COVID syndrome

    by O.V. Kotova, E.V. Tsareva, V.E. Medvedev, A.A. Belyaev, E.V. Gushanskaya, V.I. Frolova, I.G. Kotelnikova

    В 2019 г. началась пандемия, вызванная вирусом SARS-CoV-2. Борьба с COVID-19 потребовала введения ряда ограничительных мер, в частности карантина для населения и изоляции заболевших, что наряду с непосредственным влиянием вируса на нервную систему привело к значительному распространению нарушений сна. В связи с этим стали актуальными вопросы о выборе препаратов для коррекции нарушений сна, о том, какие снотворные препараты будут безопасны в условиях острого заболевания и в период восстановления после COVID-19. В статье обсуждаются проблемы распространенности и терапии инсомнии у пациентов с острым COVID-19 и с постковидным синдромом (ПКС). Описываются фармакологические эффекты и безопасность золпидема — небензодиазепинового снотворного препарата короткого действия, относящегося к классу имидазопиридинов, который применяют короткими курсами при инсомнии как острой и транзиторной, так и хронической. Приводятся данные о способности золпидема улучшать память после ночного сна. Оценивается возможность его применения при остром COVID-19 и ПКС.